-
公开(公告)号：US10130622B2
公开(公告)日：2018-11-20
申请号：US15288400
申请日：2016-10-07
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Katja E. Conrath , Douglas Cyr , Elsa De Lemos , Gert Jules Hector De Wilde , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Mathieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Chris Tse , Steven Emiel Van der Plas , Xueqing Wang
IPC分类号： A61K31/437 , A61K31/4545 , C07D471/04 , C07D519/00 , A61K45/06 , G01N33/50
摘要： A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
-
![N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE](/abs-image/US/2017/04/13/US20170101405A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170101405A1
公开(公告)日：2017-04-13
申请号：US15287911
申请日：2016-10-07
申请人： AbbVie S.à.r.l , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Em iel Van der Plas , Xueqing Wang , Ann de Blieck
IPC分类号： C07D471/04 , A61K31/4545 , A61K31/437 , A61K31/506 , A61K45/06 , A61K31/5377
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
![N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use](/abs-image/US/2019/10/31/US20190330207A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190330207A1
公开(公告)日：2019-10-31
申请号：US16444495
申请日：2019-06-18
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC分类号： C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/4545 , C07D519/00 , A61K31/437 , A61K31/506
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US20190055229A1
公开(公告)日：2019-02-21
申请号：US16165662
申请日：2018-10-19
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Robert J. Altenbach , Andrew Bogdan , Ghjuvanni Petru Diunisu Coti , Marlon D. Cowart , Stephen N. Greszler , Hans Kelgtermans , Philip R. Kym , Steven Emiel Van der Plas , Xueqing Wang
IPC分类号： C07D413/04 , C07D417/14 , C07D417/04 , A61K31/444 , A61K45/06 , A61K31/4439 , C07D413/14
摘要： The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
-
![N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE](/abs-image/US/2018/04/19/US20180105522A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180105522A1
公开(公告)日：2018-04-19
申请号：US15843917
申请日：2017-12-15
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC分类号： C07D471/04 , A61K45/06 , A61K31/437 , C07D519/00 , A61K31/506 , A61K31/5377 , A61K31/4545
CPC分类号： C07D471/04 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00 , A61K2300/00
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US20170349576A1
公开(公告)日：2017-12-07
申请号：US15602892
申请日：2017-05-23
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Robert J. Altenbach , Andrew Bogdan , Ghjuvanni Petru Diunisu Coti , Marlon D. Cowart , Stephen N. Greszler , Hans Kelgtermans , Philip R Kym , Steven Emiel Van der Plas
IPC分类号： C07D413/04 , C07D417/04 , C07D413/14 , A61K45/06 , A61K31/444 , C07D417/14 , A61K31/4439
CPC分类号： C07D413/04 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D413/14 , C07D417/04 , C07D417/14
摘要： The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
-
公开(公告)号：US09840513B2
公开(公告)日：2017-12-12
申请号：US15205512
申请日：2016-07-08
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Robert J. Altenbach , Andrew Bogdan , Marlon D. Cowart , William Ramesh Esmieu , Gregory A. Gfesser , Stephen N. Greszler , John R. Koenig , Philip R. Kym , Bo Liu , Karine Fabienne Malagu , Sachin V. Patel , Marc J. Scanio , Xenia B. Searle , Eric Voight , Xeuquing Wang , Ming C. Yeung
IPC分类号： C07D493/04 , C07D317/70 , C07D405/12 , C07D407/12 , C07D519/00 , A61K31/357 , A61K31/397 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06
CPC分类号： C07D493/04 , A61K31/357 , A61K31/397 , A61K31/433 , A61K31/443 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D317/70 , C07D405/12 , C07D407/12 , C07D519/00
摘要： The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
![SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE](/abs-image/US/2017/04/13/US20170101406A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170101406A1
公开(公告)日：2017-04-13
申请号：US15287922
申请日：2016-10-07
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V Patel , Mathieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang
IPC分类号： C07D471/04 , A61K31/5377 , C07D519/00 , A61K31/496 , A61K31/541 , A61K31/506 , A61K45/06 , A61K31/437
CPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D519/00 , A61K2300/00
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
![N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use](/abs-image/US/2020/05/12/US10647717B2/abs.jpg.150x150.jpg)
公开(公告)号：US10647717B2
公开(公告)日：2020-05-12
申请号：US16444495
申请日：2019-06-18
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Rhalid Akkari , Luke Jonathan Alvey , Xavier Marie Bock , Brian S. Brown , Pieter Isabelle Roger Claes , Marlon D. Cowart , Elsa De Lemos , Nicolas Desroy , Béranger Duthion , Gregory A. Gfesser , Romain Luc Marie Gosmini , Christopher Gaëtan Housseman , Koen Karel Jansen , Jianguo Ji , Philip R. Kym , Jean-Michel Lefrancois , Oscar Mammoliti , Christel Jeanne Marie Menet , Nuria Merayo Merayo , Gregory John Robert Newsome , Adeline Marie Elise Palisse , Sachin V. Patel , Matthieu Rafaël Pizzonero , Anurupa Shrestha , Elizabeth C. Swift , Steven Emiel Van der Plas , Xueqing Wang , Ann de Blieck
IPC分类号： C07D471/04 , A61K31/437 , C07D519/00 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06
摘要： The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
-
公开(公告)号：US10604515B2
公开(公告)日：2020-03-31
申请号：US16165662
申请日：2018-10-19
申请人： AbbVie S.à.r.l. , Galapagos NV
发明人： Robert J. Altenbach , Andrew Bogdan , Ghjuvanni Petru Diunisu Coti , Marlon D. Cowart , Stephen N. Greszler , Hans Kelgtermans , Philip R. Kym , Steven Emiel Van der Plas , Xueqing Wang
IPC分类号： C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , A61K31/4439 , A61K31/444 , A61K45/06
摘要： The invention discloses compounds of Formula I, wherein X1, X2, R1, and R2 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.042 秒)
